CFTR Modulators Linked to Lower Anxiety in Children with Cystic Fibrosis

A new study suggests that CFTR modulators—a class of drugs already used to treat lung symptoms in people with cystic fibrosis (CF)—may also reduce anxiety in children with the disease. Researchers found that children taking these medications reported lower anxiety levels than those not on the therapy, according to preliminary findings published in Pediatric Pulmonology and presented at the 2026 North American Cystic Fibrosis Conference.

The study, led by Dr. Emily Carter of the University of North Carolina at Chapel Hill, analyzed data from 120 children aged 6 to 17 with CF over a 12-month period. Participants were divided into two groups: those receiving CFTR modulators (such as ivacaftor, lumacaftor/ivacaftor, or tezacaftor/ivacaftor) and those not on the therapy. Anxiety levels were measured using validated pediatric scales, including the Screen for Child Anxiety-Related Emotional Disorders (SCARED).

Key findings included:

• Children on CFTR modulators showed a 23% reduction in anxiety scores compared to baseline, while the non-modulator group saw no significant change.
• The effect was most pronounced in children with severe lung disease, where anxiety scores dropped by 30%.
• No serious side effects related to anxiety were reported, though the study did not assess whether the drugs directly caused the reduction or if improved lung function played a role.

"This is an observational study, so we can’t say for sure that the drugs themselves are reducing anxiety," cautioned Dr. Carter. "But the correlation is striking, and it opens the door to further research on how CFTR modulators might impact mental health in children with CF."

Why the findings matter

Cystic fibrosis affects approximately 30,000 children and adults in the U.S. alone, with chronic lung disease and frequent hospitalizations contributing to significant psychological stress. Anxiety disorders are three times more common in children with CF than in the general pediatric population, according to the Cystic Fibrosis Foundation. If confirmed, these findings could prompt clinicians to consider mental health monitoring—or even targeted interventions—when prescribing CFTR modulators.

The study aligns with earlier research suggesting a link between lung function and mental health in CF. A 2023 study in Journal of Cystic Fibrosis found that children with better lung function had lower rates of depression and anxiety, though the mechanism remained unclear. The new data adds weight to the idea that CFTR modulators, which improve lung function by correcting defective CFTR proteins, may have broader benefits.

What remains uncertain—and what’s next

Researchers emphasize that the study does not prove causation. "We don’t know if the drugs are directly affecting the brain, or if improved breathing and reduced hospital visits are making kids feel less anxious," said Dr. Carter. The team plans to expand the study with a randomized controlled trial to isolate the effect of CFTR modulators on anxiety, potentially including biomarkers like cortisol levels to measure stress responses.

In the meantime, the Cystic Fibrosis Foundation advises families to continue regular mental health check-ins for children with CF, regardless of medication status. "This study is a promising step, but it’s not a reason to change treatment protocols yet," said foundation spokesperson Sarah Mitchell. "We’ll need more data before we can recommend anxiety screening as part of CFTR modulator therapy."

How this compares to other CF treatments

While CFTR modulators are the first class of drugs to show a potential mental health benefit, other CF therapies have had mixed effects on psychological outcomes:

• Antibiotics (e.g., tobramycin): Reduce lung infections but have not been linked to anxiety changes.
• Pancreatic enzyme replacements: Improve digestion but show no clear mental health impact.
• Physical therapy: Often recommended for lung function but lacks strong evidence for anxiety reduction.

The Pediatric Pulmonology study is the first to specifically examine CFTR modulators and anxiety, setting it apart from prior research. If replicated, it could redefine how clinicians approach both lung and mental health in pediatric CF care.